The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix JJL. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25(29):3870–3896. doi:10.3748/wjg.v25.i29.3870
   PubMed Web of Science ®Google Scholar
• Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–245. doi:10.1038/nrc2091
   PubMed Web of Science ®Google Scholar
• Dai X, Theobard R, Cheng H, Xing M, Zhang J. Fusion genes: a promising tool combating against cancer. Biochim Biophys Acta Rev Cancer. 2018;1869(2):149–160. doi:10.1016/j.bbcan.2017.12.003
   Web of Science ®Google Scholar
• Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet. 2010;11(12):819–829. doi:10.1038/nrg2883
   Web of Science ®Google Scholar
• Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15(6):371–381. doi:10.1038/nrc3947
   PubMed Web of Science ®Google Scholar
• Pederzoli F, Bandini M, Marandino L, et al. Targetable gene fusions and aberrations in genitourinary oncology. Nat Rev Urol. 2020;17(11):613–625. doi:10.1038/s41585-020-00379-4
   Web of Science ®Google Scholar
• Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3(1):47. doi:10.1186/1756-8722-3-47
   Web of Science ®Google Scholar
• Kong X, Pan P, Sun H, et al. Drug discovery targeting Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2019;62(24):10927–10954. doi:10.1021/acs.jmedchem.9b00446
   PubMed Web of Science ®Google Scholar
• Fernandez-Banet J, Lee NP, Chan KT, et al. Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. Genomics. 2014;103(2–3):189–203. doi:10.1016/j.ygeno.2014.01.003
   Web of Science ®Google Scholar
• Zhu C, Wu L, Lv Y, et al. The fusion landscape of hepatocellular carcinoma. Mol Oncol. 2019;13(5):1214–1225. doi:10.1002/1878-0261.12479
   Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Shi L, Zhang SJ, Chen J, et al. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Mod Pathol. 2019;32(11):1646–1656. doi:10.1038/s41379-019-0307-8
   PubMed Web of Science ®Google Scholar
• Rudkin CT, Hungerford DA, Nowell PC. DNA contents of chromosome Ph1 and chromosome 21 in human chronic granulocytic leukemia. Science. 1964;144(3623):1229–1231. doi:10.1126/science.144.3623.1229
   Web of Science ®Google Scholar
• Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234–1244. doi:10.1016/S0140-6736(11)61177-X
   PubMed Web of Science ®Google Scholar
• Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet. 2012;44(4):461–466. doi:10.1038/ng.1107
   PubMed Web of Science ®Google Scholar
• Pal SK, Bergerot P, Dizman N, et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol. 2018;74(1):124–128. doi:10.1016/j.eururo.2018.03.032
   Web of Science ®Google Scholar
• Rosell R, Karachaliou N, Wolf J, Ou SH. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med. 2014;2(12):966–968. doi:10.1016/S2213-2600(14)70259-0
   Web of Science ®Google Scholar
• Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923–929. doi:10.1007/s40265-020-01330-y
   PubMed Web of Science ®Google Scholar
• Xu L, Hazard FK, Zmoos AF, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015;24(1):50–63. doi:10.1093/hmg/ddu418
   PubMed Web of Science ®Google Scholar
• Longerich T, Endris V, Neumann O, et al. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut. 2019;68(7):1287–1296. doi:10.1136/gutjnl-2018-317632
   Web of Science ®Google Scholar
• Dou C, Sun L, Wang L, et al. Bromodomain-containing protein 9 promotes the growth and metastasis of human hepatocellular carcinoma by activating the TUFT1/AKT pathway. Cell Death Dis. 2020;11(9):730. doi:10.1038/s41419-020-02943-7
   Web of Science ®Google Scholar
• Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5(1):4846. doi:10.1038/ncomms5846
   PubMed Web of Science ®Google Scholar
• Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378(2):F115–177. doi:10.1016/s0304-419x(98)00017-1
   Web of Science ®Google Scholar
• Oba A, Shimada S, Akiyama Y, et al. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. J Hepatol. 2017;66(5):942–951. doi:10.1016/j.jhep.2016.12.026
   PubMed Web of Science ®Google Scholar
• Moreno T, Monterde B, Gonzalez-Silva L, et al. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. Oncogene. 2021;40(16):2923–2935. doi:10.1038/s41388-021-01748-y
   Web of Science ®Google Scholar
• Shriver M, Stroka KM, Vitolo MI, et al. Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene. 2015;34(32):4248–4259. doi:10.1038/onc.2014.358
   Web of Science ®Google Scholar
• Passiglia F, Caparica R, Giovannetti E, et al. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin Investig Drugs. 2016;25(4):385–392. doi:10.1517/13543784.2016.1152261
   PubMed Web of Science ®Google Scholar
• Huang CY, Wang Y, Luo GY, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother. 2017;40(9):323–333. doi:10.1097/CJI.0000000000000187
   PubMed Web of Science ®Google Scholar
• Li XS, Li JW, Li H, Jiang T. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Biosci Rep. 2020;40:4. doi:10.1042/BSR20200459
   Web of Science ®Google Scholar
• Lanza C, Gaidano G, Cimino G, et al. Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer. 1996;15(1):48–53. doi:10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4
   Web of Science ®Google Scholar
• Alidousty C, Baar T, Martelotto LG, et al. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018;246(1):67–76. doi:10.1002/path.5110
   PubMed Web of Science ®Google Scholar
• Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148(1–2):59–71. doi:10.1016/j.cell.2011.12.013
   PubMed Web of Science ®Google Scholar
• Donehower LA, Soussi T, Korkut A, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(5):1370–1384 e1375. doi:10.1016/j.celrep.2019.07.001
   PubMed Web of Science ®Google Scholar
• Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29(10):2068–2075. doi:10.1093/annonc/mdy333
   PubMed Web of Science ®Google Scholar
• Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112(1):44–50. doi:10.1002/ijc.20279
   PubMed Web of Science ®Google Scholar
• Han JH, Kim DG, Na GH, et al. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol. 2014;20(45):17132–17140. doi:10.3748/wjg.v20.i45.17132
   Web of Science ®Google Scholar
• Marasco G, Colecchia A, Colli A, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol. 2019;70(3):440–448. doi:10.1016/j.jhep.2018.10.022
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845–4854. doi:10.1038/onc.2014.406
   PubMed Web of Science ®Google Scholar
• Sato Y, Itoh F, Hareyama M, et al. Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol. 1999;34(4):486–493. doi:10.1007/s005350050301
   Web of Science ®Google Scholar
• Kang HJ, Haq F, Sung CO, et al. Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a Large Cohort Study. Liver Cancer. 2019;8(1):12–23. doi:10.1159/000488541
   Web of Science ®Google Scholar
• Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 2011;19(3):347–358. doi:10.1016/j.ccr.2011.01.040
   PubMed Web of Science ®Google Scholar
• Tan AC, Seet AOL, Lai GGY, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol. 2020;15(12):1928–1934. doi:10.1016/j.jtho.2020.08.011
   PubMed Web of Science ®Google Scholar
• Blagih J, Zani F, Chakravarty P, et al. Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep. 2020;30(2):481–496 e486. doi:10.1016/j.celrep.2019.12.028
   PubMed Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. doi:10.1186/s12943-018-0782-4
   PubMed Web of Science ®Google Scholar